Drug Dosage
The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any change in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.

All rights reserved.
No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.

© Copyright 1989 by S. Karger AG, P.O. Box, CH-4009 Basel (Switzerland)
Printed in Switzerland by Thür AG Offsetdruck, Prattein
ISBN 3-8055-4837-0

Contents

Dedication VII
Foreword IX
Acknowledgements

Moss, W. (Portland, Oreg.): Historical Perspective of Normal Tissue Tolerance or Stumbling Along the Pathway of Dose Response to Necrosis and Back 1
Travis, E. L.; Terry, H. A. (Houston, Tex.): Cell Depletion and Initial and Chronic Responses in Normal Tissues 41
van der Schueren, E.; Landuyt, W.; Scalliet, P. (Leuven): Repair of "Sublethal Damage" Key Factor in Normal Tissue Tolerance to Fractionated and Low-Dose
Irradiation 60
Fajardo, L. F. (Palo Alto, Calif.): Morphologic Patterns of Radiation Injury 75
Fajardo, L.F. (Palo Alto, Calif.): Unique Physiology of Endothelial Cells and Its Implications in Radiobiology 96
Thames, H. D.; Peters, L. J.; Ang, K. (Houston, Tex.): Time-Dose Considerations for Normal-Tissue Tolerance 113
Hoppe, R. T. (Stanford, Calif.): Effects of Irradiation on the Human Immune System 140
Rodriguez, R.; Fontanessi, J. (San Francisco, Calif, and Martinez, Calif.); Meyer, J. L.; Vaeth, J. (San Francisco, Calif.); Rounsaville, M. (Martinez, Calif.);
Vogt, P. (Martinez, Calif, and Davis, Calif.): Normal-Tissue Effects of Irradiation for Kaposi's Sarcoma/AIDS 150
Discussion 160
Meyer, J.L. (San Francisco, Calif.); Kapp, D.S. (Stanford, Calif.): Normal-Tissue Effects of Hyperthermia 162
Phillips, T. L. (San Francisco, Calif.): Chemical Modifiers of Normal-Tissue Radiation Injury 177

Contents VI

Parker, R.G.; Burnison, CM.; Sadeghi, A. (Los Angeles, Calif.): Normal-Tissue Tolerance to Fast-Neutron Teletherapy 185
Kinsella, T.J. (Madison, Wise); Sindelar, W.F. (Bethesda, Md.): Normal Tissue Tolerance to Intraoperative Radiation Therapy. Experimental and Clinical Studies 202
Parker, R. G.; Karon, D. (Los Angeles, Calif.): Normal-Tissue Tolerance of Skin, Cartilage and Bone 215
Million, R. R.; Parsons, J. T.; Mendenhall, W. M. (Gainesville, Fla.): Effect of Radiations on Normal Tissues in the Head and Neck. Bone, Cartilage, and Soft Tissue 221
Discussion 251
McDonald, S.; Rubin, P. (Rochester, N.Y.); Maasilta, P. (Helsinki): Response of Normal Lung to Irradiation Tolerance Doses/Tolerance Volumes in Pulmonary Radiation Syndromes 255
To my daughter, Cullyn, and wife, Aurore, whose dedication and efforts contributed so much to this successful twenty-third symposium.

Foreword

In 1970, our 6th San Francisco Cancer Symposium and the subsequent volume 6 of Frontiers of Radiation Therapy and Oncology addressed the subject of the effects of ionizing radiations on normal tissues. The volume was enthusiastically received and quickly became the reference text for radiation tolerance. Much in addition to time has elapsed in that 18 years. Prior to 1970, most of the concepts of irradiated normal-tissue tolerance were based on 'so-called' conventional treatment schemes - 6,000 rad in 6 weeks, delivered daily five times weekly. In today's treatment programs, 'six in six' is almost the exception. Even established concepts of tolerance must now be reexamined in the light of new knowledge of the immune system, sensitizers, modifiers, chemotherapy, and altered fractionation schemes. We have yet to develop a vocabulary for defining and comparing the quality and quantity of normal-tissue
tolerance. There is now an accumulation of both basic and clinical
data enabling us to reexamine the older concepts and formulate the
new. On March 4 and 5, 1988, a distinguished faculty, many of whom
addressed the 6th San Francisco Symposium, joined us in San Francisco
and addressed this challenge. The presentations assembled in this 23rd
volume of this series are vital to the safe utilization of radiations in the
treatment of cancers.
The symposium was produced under the auspices of the St. Mary's
Foundation, in association with St. Mary's Hospital and Medical Center,
San Francisco, Calif., USA.

Jerome M. Vaeth

Acknowledgements

The production of this year's symposium, leading to the 23rd volume
of this series, was assisted by the generosity of donations made by Alpha
Omega Services, Inc., Biotherapeutics, CIS-US, CliniTherm, Computerized
Medical Systems, Dianon Systems, Inc., Gammex, Inc., Haynes
Radiation, Northern California Radiation Therapists and Oncologists,
Roy, Siemens Corp., Therogenics Corp., Varian, Victoreen, and Wyeth
Laboratories.